TIAA CREF Investment Management LLC Invests $930,000 in Assembly Biosciences, Inc. (ASMB)
TIAA CREF Investment Management LLC acquired a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 45,053 shares of the biopharmaceutical company’s stock, valued at approximately $930,000. TIAA CREF Investment Management LLC owned 0.26% of Assembly Biosciences at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Acadian Asset Management LLC grew its stake in shares of Assembly Biosciences by 58.2% during the 2nd quarter. Acadian Asset Management LLC now owns 16,336 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 6,011 shares during the period. Parametric Portfolio Associates LLC acquired a new stake in Assembly Biosciences in the 1st quarter valued at $226,000. Renaissance Technologies LLC acquired a new stake in Assembly Biosciences in the 1st quarter valued at $242,000. Legal & General Group Plc acquired a new stake in Assembly Biosciences in the 2nd quarter valued at $212,000. Finally, Wells Fargo & Company MN acquired a new stake in Assembly Biosciences in the 2nd quarter valued at $213,000. 72.38% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms recently issued reports on ASMB. BidaskClub raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Zacks Investment Research cut shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. Finally, Jefferies Group LLC started coverage on shares of Assembly Biosciences in a research note on Wednesday. They set a “buy” rating and a $50.00 target price on the stock.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction on Monday, October 16th. The shares were sold at an average price of $33.70, for a total transaction of $33,700.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 19.60% of the company’s stock.
Shares of Assembly Biosciences, Inc. (NASDAQ ASMB) opened at $33.80 on Friday. Assembly Biosciences, Inc. has a one year low of $11.07 and a one year high of $36.31.
TRADEMARK VIOLATION NOTICE: This story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://theolympiareport.com/2017/11/12/tiaa-cref-investment-management-llc-invests-930000-in-assembly-biosciences-inc-asmb.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.